Niraj Sharma: Andexxa – Now Voluntarily Withdrawn From the U.S. Market
Niraj Sharma, Cardiac Electrophysiologist/Cardiologist at Northside Hospital, shared on LinkedIn:
“EP Edge | BREAKING NEWS
Just when we thought reversal was the solution…
Andexxa (andexanet alfa) — the first-in-class reversal agent for factor Xa inhibitors (apixaban, rivaroxaban) — has now been voluntarily withdrawn from the U.S. market, with U.S. sales ending December 22, 2025
WHAT CHANGED?
The decision follows FDA review of post-marketing safety data and results from the ANNEXA-I confirmatory randomized trial, required after Andexxa’s 2018 accelerated approval.
Bottom line from the FDA:
The risks now outweigh the benefits.
KEY SAFETY SIGNALS (ANNEXA-I)
Compared with usual care, patients receiving Andexxa had:
Higher thrombotic events:
14.6% vs 6.9%
Higher thrombotic-related deaths at 30 days:
2.5% vs 0.9%
Earlier thrombotic events:
53% of Andexxa-treated patients had earlier events vs 6.3% with usual care
Importantly, Andexxa already carried a boxed warning, but these findings confirmed a clinically meaningful safety signal, not just a theoretical risk
A REGULATORY LESSON
Accelerated approval was based on anti-FXa activity reduction (a surrogate endpoint)
The required outcomes trial failed to confirm net clinical benefit
This is exactly why post-approval trials matter
WHY THIS MATTERS TO PRACTICE
This is not just about one drug.
- Loss of the only specific Xa reversal agent in the U.S.
- Forces re-evaluation of DOAC bleeding protocols
- Reinforces caution with surrogate endpoints
- Highlights the need for safer reversal strategies
EP EDGE TAKEAWAY
Innovation is essential —
but safety must survive real-world evidence.
As clinicians, we owe our patients both speed and certainty.”
Get insights from Hemostasis Today.
-
May 19, 2026, 16:41Selina Marwa: Strengthening Sickle Cell Disease Prevention and Care in Africa
-
May 19, 2026, 16:34Congratulations to the NNHF Project of the Year 2026 Winner
-
May 19, 2026, 16:32Veronica Sanchez: Early Screening Matters in CKM Syndrome
-
May 19, 2026, 16:24Fredrick Chalinga: The Science Behind Recombinant Factor VIIa in Hemophilia A
-
May 19, 2026, 16:15Najmul Hasan Forhad: VWF Concentrates in Modern Hematology and Transfusion Medicine
-
May 19, 2026, 16:10Anirban Sen Gupta: Lyophilized Synthetic Platelets as a Stable Powder for Rapid Hemorrhage Control
-
May 19, 2026, 16:02Stroke Foundation Contributes to National Roundtable on Women’s Cardiovascular Health
-
May 19, 2026, 15:57Explore the Emerging Science Behind Factor XI/XIa Inhibition on the ISTH Academy – ISTH
-
May 19, 2026, 15:55Highlighting Key Achievements and Critical Updates from Iran’s National Blood System – IBTO